CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 23 filers reported holding CATABASIS PHARMACEUTICALS IN in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $136,000 | +100.0% | 170,293 | +140.0% | 0.00% | – |
| Q2 2018 | $68,000 | +7.9% | 70,945 | +103.7% | 0.00% | – |
| Q1 2018 | $63,000 | +18.9% | 34,828 | -1.8% | 0.00% | – |
| Q4 2017 | $53,000 | -26.4% | 35,450 | +4.4% | 0.00% | – |
| Q3 2017 | $72,000 | +44.0% | 33,950 | -3.8% | 0.00% | – |
| Q2 2017 | $50,000 | +56.2% | 35,289 | +79.5% | 0.00% | – |
| Q1 2017 | $32,000 | – | 19,656 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $4,572,000 | 5.05% |
| Clarus Ventures, LLC | 2,752,488 | $4,404,000 | 3.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 388,030 | $621,000 | 0.12% |
| Rhenman & Partners Asset Management AB | 310,756 | $497,000 | 0.08% |
| BOSTON FAMILY OFFICE LLC | 24,467 | $39,000 | 0.01% |
| OPPENHEIMER & CO INC | 90,000 | $144,000 | 0.00% |
| Alyeska Investment Group, L.P. | 221,281 | $354,000 | 0.00% |
| A.R.T. Advisors, LLC | 46,747 | $74,000 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 101,347 | $162,000 | 0.00% |
| Acrospire Investment Management LLC | 680 | $1,000 | 0.00% |